Clinical Trial

Speech-derived Digital Biomarkers Study

Completed
View on ClinicalTrials.gov →
Summary
The goal is to assess the accuracy of an application that analyzes voice characteristics to diagnose patients with mild cognitive impairment (MCI) and Alzheimer's disease (AD). The main question is whether the application's diagnosis is the same as the clinician's for MCI and AD patients.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-20; most recent amendment 2026-01-12.
Status change: Recruiting → Completed 2026-01-12
Trial Details
NCT Number NCT06994767
Lead Sponsor Hackensack Meridian Health
Collaborators: Canary Speech Inc.
Conditions Mild Cognitive Impairment (MCI), Alzheimer Disease
Enrollment 150 participants
Start Date 2025-05-19
Primary Completion 2026-01-09 (estimated)
Study Completion 2026-01-09 (estimated)
Updated on ClinicalTrials.gov 2026-01-13